Technology Networks spoke with Gil Van Bokkelen, CEO of Athersys, to learn more about MultiStem and the main mechanisms of action the cells have on the body. Gil also discussed some of the additional indications that the cells are being investigated as potential therapies for, including ischemic stroke and acute respiratory distress syndrome (ARDS).Read More
To learn more about plasma viscosity and how it can be measured, as well as understand how this information could potentially be used to help diagnose and treat COVID-19 patients, Technology Networks spoke with Bernie Benson, MD of Benson Viscometers.
This article provides tips and tricks for efficient delivery of CRISPR genome editing technology into primary cells and cell lines.Read More
Codexis and Molecular Assemblies recently announced a partnership through which the companies aim to engineer enzymes that will optimize the process of enzymatic DNA synthesis – an alternative approach to chemical DNA synthesis. Technology Networks spoke with Codexis to find out how this will transform the field of DNA synthesis.Read More
Technology Networks spoke with James Graham, Executive Director at Recce Pharmaceuticals, to learn more about how synthetic antibiotics differ from those derived from natural sources. He also discusses how the company has developed a novel class of synthetic antibiotics and elaborates on their mechanism of action.Read More
Lab-based informatics systems, such as LIMS and ELNs, are becoming more commonly used in labs. We spoke with Jeff Carter, co-founder and COO of lab software company Arxspan, to discover how COVID-19 has helped drive digitization and how tools are developing to become more flexible and connected.
Technology Networks recently spoke with David Younger, PhD, Co-founder and CEO of A-Alpha Bio, to learn more about how the company has harnessed synthetic biology and next-generation sequencing techniques to measure millions of interactions between proteins in a single test tube. This enables the identification of potential drugs for the treatment of infectious diseases, including COVID-19.Read More
One of the COVID-19 vaccine candidates that received fast track designation by the FDA is mRNA-1273, developed by Moderna, a clinical stage biotechnology company. The company has shared the positive interim results from a Phase I clinical trial of the vaccine in The New England Journal of Medicine .Read More